Search clinical trials for: Infergen® (Interferon alfacon-1)

Total 1017 results

Kadmon Corporation, LLC

Withdrawn

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C (REACHSVR)

Hepatitis C
University Health Network, Toronto

Unknown

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

Influenza

Canada
Brooke Army Medical Center
InterMune

Completed

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Hepatitis C

United States
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Minneapolis Veterans Affairs Medical Center
US Department of Veterans Affairs; Kadmon Corporation, LLC; InterMune; San Diego... and other collaborators

Completed

Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial

Chronic Hepatitis C
Beth Israel Medical Center
InterMune

Completed

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

Hepatitis C

United States
Kadmon Corporation, LLC

Terminated

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (ENHANCE)

Hepatitis C

United States
Astellas Pharma Inc
Schering-Plough

Completed

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Hepatitis C

Japan
InterMune

Completed

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

Chronic Hepatitis C

United States
Mustafa Balevi,MD
Konya Numune Hospital

Completed

The Effect of Centella Asiatica Cream on Scar Tenderness Who Underwent Open Carpal Tunnel Release Surgery

To Prevent Scar Formation for Patients Underwent Surgery

Turkey
Centre Hospitalier Universitaire Vaudois
BioPartners GmbH

Completed

Phase I BP Interferon (IFN) Beta-004

Multiple Sclerosis, Relapsing-Remitting
Trio Medicines Ltd.
Biogen

Completed

Avonex®: Safety, Blood Levels and Effects (C-851)

Multiple Sclerosis (MS)

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Claudio Gobbi
Ospedale Civico, Lugano

Completed

Natalizumab De-escalation With Interferon Beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
National Eye Institute (NEI)

Completed

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

Uveitis

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study (STEADFAST)

Friedreich's Ataxia

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia (STEADFAST)

Friedreich's Ataxia

United States
National Eye Institute (NEI)

Completed

Topical Interferon Gamma for Macular Edema Secondary to Uveitis (JakStat2)

Uveitis | Anterior Uveitis

United States
Nantes University Hospital

Active, not recruiting

Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study (PREV-HAP)

Critically Ill Patients

France, Spain, Greece
National Eye Institute (NEI)
The Emmes Company, LLC

Completed

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Macular Disease | Retinal Disease

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia (STEADFAST)

Friedreich's Ataxia

United States
Biogen

Terminated

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Multiple Sclerosis

United States
Digna Biotech S.L.

Completed

A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

Chronic Hepatitis C Virus Infection | Genotype 1 | Treatment-Experienced Patients | Relapses

Spain
University of Colorado, Denver

Completed

Effect of IFN-γ on Innate Immune Cells

Chronic Granulomatous Disease

United States
Karolinska Institutet
Merck Sharp & Dohme LLC

Completed

Nordic Adjuvant IFN Melanoma Trial

Melanoma | Adjuvant Therapy

Sweden
University of Turin, Italy
Dimensione Ricerca s.r.l.

Completed

Optimizing IFN Beta - 1B Dose (Optims)

Multiple Sclerosis
University of Birmingham
Novartis; National Cancer Institute, France; MPN Voice

Recruiting

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE)

Polycythemia Vera

United Kingdom
Sawa Ito, MD
Horizon Pharma USA, Inc.

Completed

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Myelodysplastic Syndromes | Myeloid Leukemia | Allogeneic Stem Cell Transplantation

United States
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Duke University

Terminated

Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Cancer
Intarcia Therapeutics

Completed

Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

Hepatitis C

Russian Federation
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Lee's Pharmaceutical Limited

Completed

Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

HPV Infection
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
EMD Serono

Terminated

Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Crohn's Disease

Germany, Italy, Sweden, Switzerland, United Kingdom
Bayer

Completed

BEYOND Pilot Study

Multiple Sclerosis | Relapsing-Remitting

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
Hospices Civils de Lyon
Novartis

Unknown

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PETALs)

Chronic Myeloid Leukemia

France
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Synairgen Research Ltd.

Completed

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Asthma

United Kingdom
Bayer

Completed

Betaferon® Regulatory Post-Marketing Surveillance

Multiple Sclerosis | Clinically Isolated System

Korea, Republic of
PD Dr. Marcus Müller
BfARM, Bonn; DZNE, Bonn

Unknown

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Relapsing-remitting Multiple Sclerosis

Germany

Search clinical trials for: Infergen® (Interferon alfacon-1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations